GHP Q1 2021

12 GHP / Q1 2021 , Nov20615 Medicine and healthcare are industries that are always subject to the ever-moving world of innovation. Being constantly subject to innovationmeans that these industries are often being introduced to new technologies and techniques, or processes and procedures. Today, we at Global Health and Pharma are highlighting the work of NINAMedical, which has earned 2021’s Award for Excellence inNon-Invasive Surgery Solutions. Join us as we profile what it offers and how it has earned this coveted award title. NINA Medical Makes Marvels Working towards next-generation medicine, NINA Medical is focusing on the vision of noninvasive surgery. The general idea is to replace the doctor’s scalpel with a beam of energy that penetrates the body of the patient, inducing a controlled modification to a target tissue, in order to achieve a specific medical outcome. Non-invasive surgery has been gaining traction over the years, with many choosing this option over traditional surgery. NINA Medical develops a non-invasive technology for high-energy ultrasound radiation capable of burning a selected point inside the body. The company is an innovator in this field and as such, it was awarded the 2021 Award for Excellence in Non-Invasive Surgery Solutions by Global Health and Pharma Magazine. NINA Medical is founded on the motto of “Treatment Without Trauma”. The team is passionate about non-invasive solutions that are at the forefront of the medical technology. Delivering this high-energy ultrasound radiation beam is right there, spearheading what the medical industry is currently doing. The process works as follows: Ultrasound energy is transmitted and focused so that the intensity reaches extremely high values at the focal point, inducing a thermal effect at the focal point alone. This causes selective ablation to the target tissue, leaving the surrounding tissue intact. NINA Medical’s proprietary technology facilitates guided treatment by means of diagnostic ultrasound, meaning that the user can actually visualize the focal point inside the body in real-time. This enables the physician to control the high energy beam and bring the focal point to the target tissue. NINA Medical is gradually earning its reputation for being a pioneer in this emerging field of image guided high intensity focused ultrasound, otherwise known as HIFU. Being active in this field has allowed the company to introduce a set of patent-pending inventions that aim to boost the adoption of HIFU as an acceptable modality for non-invasive surgery. At present, although its product is still in the development phase, NINA Medical has a bright future ahead, especially in light of global trends leaning towards less invasive treatment solutions. Primary beneficiaries from the work being carried out by NINA Medical include men at the third age who suffer from symptoms of the enlarged prostate, also known as benign prostatic hyperplasia (BPH). Sometimes considered to be part of the normal ageing process of men, the condition affects more than 50% of men above age of 55. BPH is a progressive condition in which the prostate grows and gradually blocks the urethra, diminishing the flow of urine from the bladder. Symptoms include difficulties in urination, the frequent and urgent need to urinate, and nocturia, all of which have a negative effect on quality of life. Existing treatment options include medications as a firstline treatment and minimally invasive surgery as a secondline treatment. In more severe situations, surgery may be considered as well. Although medications are common, they do have side effects, not always tolerable by the patients. Patients usually cease medications within several years, either because of the unbearable side effects or due to degradation in pharmacological efficacy. At this stage, men start to search for options for minimally invasive surgery. Existing solutions span from supportive stent to steam injection, and they are all trans-urethral; that is, they use the urethra of the patient as a working channel for the insertion Shmuel Ben-Ezra, CEO